William Blair Has Positive Outlook for EW FY2025 Earnings

Edwards Lifesciences Corporation (NYSE:EW) – Analysts at William Blair raised their FY2025 earnings per share estimates for shares of Edwards Lifesciences in a report issued on Friday, October 31st. William Blair analyst B. Vazquez now expects that the medical research company will post earnings of $2.58 per share for the year, up from their prior forecast of $2.48. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. William Blair also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.60 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.72 EPS, Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.69 EPS, FY2026 earnings at $2.80 EPS, Q1 2027 earnings at $0.73 EPS, Q2 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.79 EPS and FY2027 earnings at $3.09 EPS.

Several other equities analysts also recently weighed in on EW. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday. Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, July 29th. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Finally, Truist Financial upped their price objective on Edwards Lifesciences from $82.00 to $87.00 and gave the company a “hold” rating in a research report on Tuesday, October 28th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $91.00.

Edwards Lifesciences Stock Performance

NYSE EW opened at $82.48 on Monday. The company has a market cap of $48.42 billion, a P/E ratio of 11.87, a P/E/G ratio of 3.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The business’s 50 day moving average price is $77.58 and its 200-day moving average price is $76.97. Edwards Lifesciences has a fifty-two week low of $64.89 and a fifty-two week high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth $26,000. SouthState Corp purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth $27,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $28,000. True Wealth Design LLC lifted its holdings in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. Finally, Rossby Financial LCC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth $29,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.